AKT1 and cancer: Since mTOR inhibition increases AKT activity by disrupting feedback inhibition [47, 48], vertical targeting of the PI3K-AKT-mTOR pathway has proven to be a promising approach in several cancer types [27–29], with clinical trials ongoing [30].